Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension

Journal of Hypertension

Volumn 21, Issue 9, 2003, Pages 1663-1667

  Bulut, Daniel ^a   Liaghat, Sina ^a   Hanefeld, Christoph ^a   Koll, Rouven ^a   Miebach, Thomas ^a   Mügge, Andreas ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Cyclo oxygenase; Endothelial function; Essential hypertension; Prostacyclin

Indexed keywords

ACETYLCHOLINE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NITROPRUSSIDE SODIUM; PARECOXIB;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR AUTOREGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; FEMALE; FOREARM BLOOD FLOW; HUMAN; MALE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; SIDE EFFECT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0042232709     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200309000-00015     Document Type: Article

References (31)

1. Lipsky PE, Brooks P, Crofford LJ, DuBois R, Graham D, Simon LS, et al. Unresolved issues in the roles of cyclooxygenase-2 in normal physiologic processes and diseases. Arch Intern Med 2000; 160:913-120.
2. FitzGerald GA, Patronio C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-442.
3. Zembowicz A, Jones SL, Wu KK. Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine. J Clin Invest 1995; 96:1688-1692.
4. Topper JN, Cai J, Falb D, Gimbrone MA. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA1996; 93:10417-10422.
5. Baker CSR, Hall RJC, Evans TJ, Pomerance A, Maclouf J, Creminon C, et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colonizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 1999; 19:646-655.
6. Mukherjee D, Nissen SE, Topoi EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
7. Muscara MN, Vergnolle N, Lovren F, Triglle CR, Elliot SN, Asfaha S, Wallace JL. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000; 129:1423-1430.
8. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104:820-825.
9. Verma S, Raj SR, Shewchuk L, Mather KJ, Anderson TJ. Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers. Circulation 2001; 104:2879-2882.
10. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25:918-923.
11. Cheer SM, Goa KL. Parecoxib (parecoxib sodium). Drugs 2001; 61:1133-1141.
12. Husted SE, Kristensen SD, Vissinger H, et al. Intravenous acetylsalicylic acid-dose related effects on platelet function and fibrinolysis in healthy males. Thromb Haemost 1992; 68:226-229.
13. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for the release of endothelium-derived relaxing-factor in the human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990; 81:1762-1767.
14. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
15. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
16. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21:929-933.
17. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29:274-279.
18. Taddei S, Virdis A, Ghiadori L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilation in essential hypertensive patients. J Hypertens 1998; 16:447-456.
19. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104:191-6.
20. Menobe H, Yamanari H, Nakamura K, Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin Cardiol 2001; 24:705-709.
21. Bulut D, Potthast R, Hanefeld C, Schulz T, Kuhn M, Mügge A. Impaired vasodilator responses to atrial natriuretic peptide in essential hypertension. Eur J Clin Invest 2003; 33:567-73
22. Cardillo C, Kilcoyne CM, Quyyumi AA, Cannon RO, Panza JA. Selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation 1998; 97:851-856.
23. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268:6610-6614.
24. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96:272-277.
25. Catella-Lawson F, McAdam BH, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735-741.
26. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102:840-845.
27. Duffy SJ, Castle SF, Harper RW, Meredith IT. Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation 1999; 100:1951-1957.
28. Cheng Y, Austin SC, Rocca B, Koller BH, Coffmann TM, Grosser T, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296:539-541.
29. Chenevard R, Hürlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107:405-409.
30. Crofford U, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: a report of four cases. Arthritis Rheum 2000; 43:1891-1896.
31. Mardini IA, FitzGerald GA. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. Mol Interv 2001; 1:30-38.